CD38 and neoplasm: The results (Figure 5A) show that loss of CD38 substantially and significantly reduced RMS melanoma tumor volume (7.6-fold reduction in Cd38‒/‒ mice at 14 days post-injection) and prolonged survival of the RMS melanoma-bearing mice (Figure 5B).